SG10201805207QA - Factor viii polypeptide formulations - Google Patents

Factor viii polypeptide formulations

Info

Publication number
SG10201805207QA
SG10201805207QA SG10201805207QA SG10201805207QA SG10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA
Authority
SG
Singapore
Prior art keywords
factor viii
fviii
viii polypeptide
polypeptide
polypeptide formulations
Prior art date
Application number
SG10201805207QA
Other languages
English (en)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201805207Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of SG10201805207QA publication Critical patent/SG10201805207QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201805207QA 2013-03-15 2014-03-14 Factor viii polypeptide formulations SG10201805207QA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
SG10201805207QA true SG10201805207QA (en) 2018-07-30

Family

ID=50771579

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505924TA SG11201505924TA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations
SG10201805207QA SG10201805207QA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201505924TA SG11201505924TA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Country Status (21)

Country Link
US (3) US9623088B2 (fr)
EP (3) EP2968477B1 (fr)
JP (5) JP6330026B2 (fr)
AU (3) AU2014228506A1 (fr)
CA (1) CA2899737A1 (fr)
CL (1) CL2015002720A1 (fr)
DK (1) DK2968477T3 (fr)
EA (2) EA030357B1 (fr)
ES (2) ES2776195T3 (fr)
HK (1) HK1220617A1 (fr)
HU (1) HUE047933T2 (fr)
LT (1) LT2968477T (fr)
PH (2) PH12015501801A1 (fr)
PL (2) PL3666283T3 (fr)
PT (2) PT2968477T (fr)
RS (1) RS60003B1 (fr)
SG (2) SG11201505924TA (fr)
SI (1) SI2968477T1 (fr)
TW (2) TWI690325B (fr)
UY (1) UY35462A (fr)
WO (1) WO2014144795A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782424C (fr) * 2009-12-06 2021-07-27 Biogen Idec Hemophilia Inc. Polypeptides chimeriques et hybrides de facteur viii-fc, et procedes d'utilisation de ceux-ci
UY35462A (es) * 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
AU2018366110B2 (en) * 2017-11-07 2024-08-08 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
US20220033475A1 (en) * 2018-10-23 2022-02-03 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
EP3932486A4 (fr) * 2019-02-28 2022-11-30 Public University Corporation Yokohama City University Composition de traitement de troubles de la coagulation du sang et/ou du complément
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
KR20230159285A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
WO2023219378A1 (fr) * 2022-05-10 2023-11-16 주식회사 녹십자 Nouvelle formulation liquide pour protéine plasmatique

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (fr) 1986-01-03 1987-07-16 Genetics Institute, Inc. PROCEDE DE PRODUCTION DE PROTEINES DE TYPE FACTEUR VIII:c
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (fr) 1987-04-06 1994-08-02 Randal J. Kaufman Methode de production du facteur viii : proteines de type c
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP0461200B1 (fr) 1989-02-21 1997-01-22 Washington University Formes modifiees d'hormones de reproduction
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
RU2244556C2 (ru) * 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP2277910A1 (fr) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Protéines de fusion d'albumine
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP3378470A1 (fr) * 2003-12-19 2018-09-26 Novo Nordisk Health Care AG Compositions stabilisées de polypeptides de facteur vii
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SI3130601T1 (sl) 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
KR20080098504A (ko) * 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
KR101542752B1 (ko) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
US20120093840A1 (en) 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
CA2782424C (fr) * 2009-12-06 2021-07-27 Biogen Idec Hemophilia Inc. Polypeptides chimeriques et hybrides de facteur viii-fc, et procedes d'utilisation de ceux-ci
WO2013009627A2 (fr) * 2011-07-08 2013-01-17 Biogen Idec Hemophilia Inc. Polypeptides chimériques et hybrides du facteur viii et leurs procédés d'utilisation
CA2850579A1 (fr) 2011-10-18 2013-04-25 Carsten Horn Procede pour l'amelioration de la stabilite du facteur viii purifie apres la reconstitution
JP2015527350A (ja) 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子の液体製剤
EP3943102A1 (fr) * 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Procédé d'utilisation de polypeptide du facteur viii
UY35462A (es) * 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.

Also Published As

Publication number Publication date
TWI629993B (zh) 2018-07-21
EP2968477B1 (fr) 2019-12-04
US9623088B2 (en) 2017-04-18
JP2023060146A (ja) 2023-04-27
PT3666283T (pt) 2022-09-13
EP2968477A1 (fr) 2016-01-20
JP2016516722A (ja) 2016-06-09
JP6934994B2 (ja) 2021-09-15
JP2021181491A (ja) 2021-11-25
PL3666283T3 (pl) 2022-10-03
EA201591439A1 (ru) 2016-03-31
AU2021277601A1 (en) 2021-12-23
UY35462A (es) 2014-10-31
CL2015002720A1 (es) 2016-11-04
JP2020186268A (ja) 2020-11-19
PH12015501801B1 (en) 2015-11-09
HK1220617A1 (zh) 2017-05-12
PL2968477T3 (pl) 2020-06-15
JP2018123161A (ja) 2018-08-09
US20140308280A1 (en) 2014-10-16
EP3666283A1 (fr) 2020-06-17
US20210069300A1 (en) 2021-03-11
HUE047933T2 (hu) 2020-05-28
PT2968477T (pt) 2020-03-11
SG11201505924TA (en) 2015-09-29
ES2926798T3 (es) 2022-10-28
RS60003B1 (sr) 2020-04-30
PH12019502452A1 (en) 2021-02-08
CA2899737A1 (fr) 2014-09-18
LT2968477T (lt) 2020-03-10
US10786554B2 (en) 2020-09-29
ES2776195T3 (es) 2020-07-29
TW201842930A (zh) 2018-12-16
TW201501722A (zh) 2015-01-16
PH12015501801A1 (en) 2015-11-09
EA201890671A1 (ru) 2019-01-31
JP6330026B2 (ja) 2018-05-23
TWI690325B (zh) 2020-04-11
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
DK2968477T3 (da) 2020-03-09
EA030357B1 (ru) 2018-07-31
WO2014144795A1 (fr) 2014-09-18
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
EP3666283B1 (fr) 2022-06-08
AU2014228506A1 (en) 2015-08-13
JP7240457B2 (ja) 2023-03-15
EP4122487A1 (fr) 2023-01-25

Similar Documents

Publication Publication Date Title
PH12019502452A1 (en) Factor viii polypeptide formulations
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
PH12017500042A1 (en) Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use
MX2021005907A (es) Formulaciones de proteinas liquidas que contienen liquidos ionicos.
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
EP3341400A4 (fr) Protéine recombinante (cp-bmp) de protéine morphogénétique osseuse perméable aux cellules et son utilisation
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
IL262568A (en) Inactive material based on proteins for active pharmaceutical ingredients
TW201613557A (en) Stable aqueous recombinant protein formulations
MX2017003121A (es) Formulaciones de anticuerpos.
EP3476937A4 (fr) Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
EP3362048A4 (fr) Composition destinée à une administration intra-orale de peptides et de protéines biologiquement actifs
MX2015016492A (es) Peptidos de y conotoxina, composicion farmaceutica y usos de los mismos.
MX2013012337A (es) Composiciones y metodos.
SG10201803999UA (en) Recombinant factor viii formulations
IL283229A (en) High concentration protein formulation
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
AR122764A2 (es) Formulación de un polipéptido del factor viii, kit farmacéutico, método
EP3416677A4 (fr) Composition pharmaceutique comprenant hgh recombinant pour le traitement d'un déficit en hormone de croissance
EP3334755A4 (fr) Protéine recombinante de facteur de reprogrammation à perméabilité cellulaire améliorée (icp-rf), et utilisation de ladite protéine
MX2016008170A (es) Proteinas de fusion que comprenden factor ix para tratamiento profilactico de hemofilia y metodos para este.
IN2014MU00077A (fr)
AR095431A1 (es) Formulaciones de fviii recombinante